KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$913.0 million.

  • Xenon Pharmaceuticals' Enterprise Value fell 3960.08% to -$913.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$913.0 million, marking a year-over-year decrease of 3960.08%. This contributed to the annual value of -$1.2 billion for FY2024, which is 9411.2% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Enterprise Value of -$913.0 million as of Q3 2025, which was down 3960.08% from -$977.0 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Enterprise Value high stood at -$249.6 million for Q3 2021, and its period low was -$1.2 billion during Q4 2024.
  • Moreover, its 5-year median value for Enterprise Value was -$592.1 million (2022), whereas its average is -$625.2 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Enterprise Value crashed by 21174.2% in 2021, and later soared by 3154.35% in 2023.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Enterprise Value stood at -$551.8 million in 2021, then fell by 7.31% to -$592.1 million in 2022, then fell by 7.77% to -$638.1 million in 2023, then tumbled by 94.11% to -$1.2 billion in 2024, then rose by 26.29% to -$913.0 million in 2025.
  • Its last three reported values are -$913.0 million in Q3 2025, -$977.0 million for Q2 2025, and -$549.6 million during Q1 2025.